Gainers

• Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.6 million. As per the news, the Q2 earnings report came out 4 days ago.
• Moderna (NASDAQ:MRNA) stock moved upwards by 97.35% to $124.25. The company's market cap stands at $24.9 billion.
• Arcturus Therapeutics (NASDAQ:ARCT) shares moved upwards by 58.85% to $13.04. The market value of their outstanding shares is at $233.3 million.
• BioVie (NASDAQ:BIVI) stock rose 39.96% to $1.35. The company's market cap stands at $7.2 million. As per the press release, Q4 earnings came out 4 days ago.
• Virax Biolabs Group (NASDAQ:VRAX) shares moved upwards by 19.2% to $3.29. The market value of their outstanding shares is at $2.1 million.
• AEON Biopharma (AMEX:AEON) stock moved upwards by 17.42% to $0.29. The company's market cap stands at $12.2 million.

Losers

• AIxCrypto Hldgs (NASDAQ:AIXC) shares declined by 15.2% to $1.12 during Wednesday's pre-market session. The market value of their outstanding shares is at $26.7 million.
• Akanda (NASDAQ:AKAN) stock declined by 12.76% to $4.24. The company's market cap stands at $2.6 million.
• bioAffinity Technologies (NASDAQ:BIAF) shares decreased by 11.92% to $0.42. The market value of their outstanding shares is at $3.8 million.
• Cosmos Health (NASDAQ:COSM) stock decreased by 11.43% to $0.18. The company's market cap stands at $12.8 million. As per the press release, Q2 earnings came out yesterday.
• XTL Biopharmaceuticals (NASDAQ:XTLB) shares decreased by 11.15% to $2.87. The company's market cap stands at $7.9 million.
• SILO Pharma (NASDAQ:SILO) stock fell 11.08% to $2.73. The market value of their outstanding shares is at $4.8 million. As per the press release, Q2 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.